Literature DB >> 8440920

Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent.

D Guerry1, M Synnestvedt, D E Elder, D Schultz.   

Abstract

Primary melanoma generally evolves through three clinically and morphologically discernable tumor progression steps. Transformed melanocytes first proliferate above the epidermal basement membrane, then invade the papillary dermis (the in situ and invasive radial growth phases of melanoma), and subsequently develop the capacity to grow as a tumor (the vertical growth phase). Here, we address three aspects of the invasive radial growth phase that provide the rationale for viewing it as the critical lesion for melanoma detection and therapy. We determined the fraction of melanomas having this growth phase, tested its hypothesized incapacity to metastasize, and estimated its longevity. The high prevalence of this step in tumor progression was demonstrated in a data base of 624 patients, where at least 87% of melanomas exhibited a radial growth phase. The benignity of this lesion was evinced by the perfect metastasis-free survival of 161 patients treated for pure radial growth-phase melanomas and followed for a median of 13.7 years. Its indolence was evident in an analysis of the ages of 234 patients with superficial spreading melanomas without or with vertical growth phase: The cases with lesions having only radial growth phase were 4.3 years younger than those additionally having vertical growth phase (p < 0.05). These features of the invasive radial growth phase of primary melanoma, first described by Wallace H. Clark, make it a pivotal lesion in the evolutionary biology of melanocytic neoplasia and confirm its central place in public health programs to control melanoma mortality.

Entities:  

Mesh:

Year:  1993        PMID: 8440920     DOI: 10.1111/1523-1747.ep12470248

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  26 in total

1.  Curable melanomas: seek, and ye shall find.

Authors:  D Guerry; A C Halpern
Journal:  J Gen Intern Med       Date:  1992 Mar-Apr       Impact factor: 5.128

2.  Smad7 restricts melanoma invasion by restoring N-cadherin expression and establishing heterotypic cell-cell interactions in vivo.

Authors:  Kyle A DiVito; Valerie A Trabosh; You-Shin Chen; Yu Chen; Chris Albanese; Delphine Javelaud; Alain Mauviel; Cynthia M Simbulan-Rosenthal; Dean S Rosenthal
Journal:  Pigment Cell Melanoma Res       Date:  2010-08-25       Impact factor: 4.693

3.  Automated detection of malignant features in confocal microscopy on superficial spreading melanoma versus nevi.

Authors:  Dan Gareau; Ricky Hennessy; Eric Wan; Giovanni Pellacani; Steven L Jacques
Journal:  J Biomed Opt       Date:  2010 Nov-Dec       Impact factor: 3.170

4.  Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin.

Authors:  L C van Kempen; J J van den Oord; G N van Muijen; U H Weidle; H P Bloemers; G W Swart
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

5.  Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours.

Authors:  D S Sanders; K Blessing; G A Hassan; R Bruton; J R Marsden; J Jankowski
Journal:  Mol Pathol       Date:  1999-06

6.  An observational study regarding the rate of growth in vertical and radial growth phase superficial spreading melanomas.

Authors:  Roberto Betti; Elena Agape; Raffaella Vergani; Laura Moneghini; Amilcare Cerri
Journal:  Oncol Lett       Date:  2016-07-05       Impact factor: 2.967

7.  From melanocyte to metastatic malignant melanoma.

Authors:  Bizhan Bandarchi; Linglei Ma; Roya Navab; Arun Seth; Golnar Rasty
Journal:  Dermatol Res Pract       Date:  2010-08-11

Review 8.  Use of liposomes as drug delivery vehicles for treatment of melanoma.

Authors:  Melissa A Tran; Rebecca J Watts; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-22       Impact factor: 4.693

Review 9.  From melanocytes to melanomas.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  Nat Rev Cancer       Date:  2016-04-29       Impact factor: 60.716

10.  Semaphorin 3E expression correlates inversely with Plexin D1 during tumor progression.

Authors:  Ilse Roodink; Gürsah Kats; Léon van Kempen; Meritha Grunberg; Cathy Maass; Kiek Verrijp; Jos Raats; William Leenders
Journal:  Am J Pathol       Date:  2008-10-30       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.